Treatment of NSCLC patients with tumor infiltrating lymphocyte therapies
AssigneeIovance Biotherapeutics, Inc.
InventorsMaria Fardis, Friedrich-Reinhard Graf Finck Von Finckenstein
Life of this patent
Estimating the term…
Abstract
The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody and/or anti-PD-L1 antibody and/or VEGF inhibitor, or wherein the NSCLC has a predetermined tumor proportion score (TPS).
Claims20
A method of treating non-small cell lung cancer (NSCLC) in a patient in need thereof, the method comprising administering a therapeutically effective population of tumor infiltrating lymphocytes (TILs) to the patient, wherein the patient is refractory or resistant to an immune-checkpoint inhibitor (ICI) treatment, wherein the refractory or resistant NSCLC has been previously treated with an ICI and has progressed on or after the treatment with the ICI, and wherein the patient has a predetermined absence of one or more driver mutations, and wherein the one or more driver mutations comprise an EGFR mutation;
- and further wherein the TILs are administered as a single agent.
Dependencies are inferred from the claim text.